There is growing concern that the majority of modern research may be comprised of false findings, which is partly attributed to unacceptable flexibility in data analyses. Here this issue is considered in the literature suggesting that MDMA (3,4-methylenedioxymethamphetamine) may be associated with neurocognitive deficits. Research suggests that increased exposure to ecstasy is associated with decreased performance on some neuropsychological tests. This claim is supported by the fact that ''heavier'' users often perform worse than ''light'' users on neurocognitive tests. However, most studies use different criteria for defining what is considered a ''light'' or ''heavy'' ecstasy user. Here the literature was systematically reviewed to compare the criteria used across studies which compare light and heavy ecstasy users. Out of the 19 studies reviewed nine unique points of dichotomization were found. In many cases, heavy users in one study would have been considered light users in another study and vice versa. Most studies (n ¼ 11) did not explain how or justify why a particular criterion was chosen. Only eight studies provided justifications for why they chose a particular criterion and the reasons were often misleading. There are many methodological issues which bring into question the validity of research suggesting MDMA is the cause of neurocognitive deficits. Methodologists have demonstrated that it is unacceptably easy for researchers to report significant findings where no relationship exists, which may have been the case in some studies reporting on the neurocognitive deficits found in ecstasy users.
Introduction 3,4-Methylenedioxymethamphetamine (MDMA) is the active ingredient in the recreational drug ecstasy. There is an extensive body of literature suggesting that ecstasy (and hence MDMA) may cause neurocognitive deficits (Parrott, 2006; Parrott et al., 2000) . However, most meta-analyses show that the deficits found in ecstasy users are small and clinically irrelevant (Murphy et al., 2012; Nulsen et al., 2010; Roberts et al., 2016; Rogers et al., 2009 ) but even these results may be inflated (Ioannidis, 2005b) . It has been found in other areas of research that initial findings are often exaggerated and contradicted as methodologies are refined and pressure to publish novel research lessens (Ioannidis, 2005a) . This may also be the case in the ecstasy literature as effect sizes in studies showing neurocognitive deficits have decreased steadily over time (Taylor et al., 2011) . Also, publications from the United States-where there is more pressure to publish frequently for academic promotion-are more likely to be exaggerated (Fanelli and Ioannidis, 2013) . Again, Taylor et al. (2011) found this to be the case in regards to the ecstasy literature with studies from the US reporting more dramatic neurocognitive deficits in ecstasy users than those originating from Europe.
Etiological hypotheses-such as the one that ecstasy use is associated with neurocognitive deficits-often cannot be tested using randomized control trials. Instead, we must rely upon observational studies, which cannot determine causality. Individual studies do not provide substantial evidence to determine whether or not a relationship exists between ecstasy use and neurocognitive deficits. Instead studies need to be replicated and presented in meta-analyses which can provide more substantive evidence. However, metaanalyses of observational data can often produce spurious results (Egger et al., 1998) . One reason for this is the lack of random allocation to a particular exposure (i.e. ecstasy)-instead people who have already used ecstasy are recruited and they may have unique characteristics prior to using the drug (i.e. increased impulsivity and risk taking behaviors which may contribute to neurocognitive deficits). Another reason why meta-analyses of observational research can be misleading is that confounding variables cannot be precisely controlled for in the original studies they include (Phillips and Smith, 1991; Smith and Phillips, 1992) . There are several confounding variables in studies reporting on the deficits associated with ecstasy use (see Amoroso, 2016; Gouzoulis-Mayfrank and Daumann, 2006; Rogers et al., 2009 ) and each study controls for them in a unique way.
There is strong evidence that researchers looking at the effects of ecstasy have selectively published findings that support their hypotheses while failing to publish those that do not (Roberts et al., 2016; Rogers et al., 2009; Sumnall and Cole, 2005) . After MDMA became a Schedule 1 drug in 1985 research on the drug increased dramatically as laboratories in the United States and Europe raced to publish findings on its toxic effects. But as Ioannidis (2005b) points out ''hot'' or controversial research topics are at greater risk for publishing false findings. Another issue with this area of research is that there is significant inconsistency and flexibility in how studies have been designed and how data have been analyzed. Increased flexibility in analyses and unstandardized methodologies are more likely to produce results that the researcher expects to find (Fanelli and Ioannidis, 2013; Ioannidis, 2005b; Ioannidis et al., 2014; Simmons et al., 2011) . This becomes more problematic when studies with heterogeneous methodologies are combined in meta-analyses. For instance, many studies on ecstasy use compare ''light'' and ''heavy'' users, and when incorporating data into a meta-analysis, authors must decide which data to include. Some meta-analyses choose to calculate effects' sizes by comparing the control groups to only the heavy using groups (Laws and Kokkalis, 2007; Nulsen et al., 2010; Verbaten, 2003) , which has inherent bias but more concerning is that there is lack of consistency on how ''light'' and ''heavy'' users are defined across studies. This review will expand upon this issue and demonstrate the widespread flexibility in data analyses in ecstasy research. This is an important issue because standardized criteria are critical in order to prevent manipulation of research data.
Methods
Studies that compared light and heavy users were included in this review. Studies were selected if they were previously included in one of the published meta-analyses on the neurocognitive effects of ecstasy use. There were two reasons for this. First, it provided an objective way of selecting studies to be included rather than ''cherry picking'' those that supported the authors point. The second reason is that, theoretically, meta-analyses are supposed to include the highest quality studies and exclude lower quality studies.
PubMed was used to first search for the metaanalyses published on ecstasy and neurocognitive outcomes. The search terms included ecstasy OR MDMA AND meta-analysis, which resulted in 21 papers. Eleven papers were excluded because they were either not related to ecstasy or MDMA specifically or were not meta-analyses. Two meta-analyses were excluded because one reported on the clinical use of MDMA in the treatment of posttraumatic stress disorder (PTSD) (Amoroso and Workman, 2016) while the other was related to ecstasy use and risky sexual behaviors (Hittner and Schachne, 2012) . In total eight metaanalyses were selected and used to find studies that dichotomized light and heavy users. There was some variation on the language used between studies. For example, some studies used ''novice'', ''regular'', or ''moderate'' to describe their participants-but the focus of this review is to describe the points of dichotomization rather than the language used.
In total, 103 individual studies were included in the eight meta-analyses. Each study was screened to determine if ecstasy users were dichotomized and compared. After screening each paper, 19 studies were found to compare groups by amount of use. Then the criteria for dichotomization were reviewed along with a justification for why the criteria were used, if reported.
Results

Cut off points for heavy and light users
Out of the 19 studies, there were nine unique ways of dichotomizing participants. Most studies (n ¼ 8) used 50 tablets as the point for dichotomization (Back-Madruga et al., 2003; Dafters, 2006a Dafters, , 2006b Dafters et al., 2004; de Win et al., 2004; Halpern et al., 2004 Halpern et al., , 2011 Reneman et al., 2006) . Two studies used 80 tablets as the point for dichotomization (Daumann et al., 2003; Gouzoulis-Mayfrank et al., 2003) , two used 10 tablets as the point for dichotomization Parrott and Lasky, 1998) , and two studies used 20 tablets as the point for dichotomization (Parrott et al., 2000 (Parrott et al., , 2001 . The remaining five studies all had unique points of dichotomization. Bhattachary and Powell (2001) , used five tablets as their point for dichotomization (with other specific criteria). Fisk and Montgomery (2009) 
Methods and justifications for dichotomization
Most studies (n ¼ 11) did not provide any justification for how or why the particular criteria were chosen (Back-Madruga et al., 2003; Bhattachary and Powell, 2001; Dafters, 2006b Dafters, , 2006a Dafters et al., 2004; Golding et al., 2007; Montgomery et al., 2005; Parrott and Lasky, 1998; Parrott et al., , 2000 Parrott et al., , 2001 . Four studies dichotomized ecstasy users using a median split (Daumann et al., 2003; Gouzoulis-Mayfrank et al., 2003; Halpern et al., 2004 Halpern et al., , 2011 . One study used ''trial and error'' to establish a cut off of 400 tablets so that the high dose group had a mean lifetime dose of 1,000 tablets (Fisk and Montgomery, 2009) . Two studies (de Win et al., 2004; Reneman et al., 2006) justified their decision by citing a case series (Schifano and Magni, 1994) on chocolate cravings and other psychopathologies following ecstasy abuse. Finally, one study (Verkes et al., 2001 ) established a cut off ''based on recent frequency of use [past 2 years] rather than on cumulative use, because in animals damage seemed more strongly associated with the former'' but the authors did not provide a citation for the animal studies that support their justification.
Discussion
Studies reporting on the neurocognitive deficits associated with ecstasy use have used largely inconsistent and unjustified methods for establishing criteria for light and heavy users. This is problematic because the risk for false positives increases with increased flexibility in data analysis (Carp, 2012) . Regardless of these inconsistencies, dichotomizing continuous variables such as lifetime ecstasy use is not an appropriate statistical method and can lead to false positives Royston et al., 2006) . With inconsistent dichotomization of ecstasy users there is potential for manipulation of data to support the researcher's biases. For instance, if one set of analyses which defines light users as those who have consumed less than 10 tablets in their lifetime turns out insignificant, the criteria can be changed post hoc to 20 or 50 lifetime exposures and then justified by citing another study that used similar criteria.
The criteria for defining ''light'' and ''heavy'' users were often more complicated than simply establishing an arbitrary cut off for lifetime doses. Many studies included caveats that further complicated the dichotomizations. The caveats were often arbitrary yet specific, which raise question to the reasoning behind the decision. For instance, Bhattachary and Powell (2001) defined novice users as those who ''had taken MDMA between one and five times in total; never more frequently than once in a month; and at least once within the 21 days''. Twenty-one days is a specific, yet arbitrary, cut off and the decision making process must have been influenced by something important.
Some of the justifications for choosing the points of dichotomization were also found to be problematic. For instance, two studies (de Win et al., 2004; Reneman et al., 2006) justified their decision ''based on previous findings of increased risk of developing psychiatric disturbances in people with a lifetime consumption of 50 or more MDMA tablets'' (citing: Schifano and Magni, 1994) . However, Schifano and Magni (1994) is a case series on seven individuals who reported chocolate cravings and other psychopathologies following ecstasy abuse, and the article does not mention 50 lifetime doses as being a significant or critical tipping point. Another problematic justification was the one reported by Verkes et al. (2001) which was ''based on recent frequency of use [past 2 years] rather than on cumulative use, because in animals damage seemed more strongly associated with the former''. The authors did not cite any supporting preclinical research. Given the differences in both lifespan and metabolic processes between humans and animals (Green et al., 2009 ) this is likely not a valid justification. More importantly, two years is an arbitrary yet specific cut off, which may have been chosen based on how it would influence the results.
There is statistical evidence showing that publication bias in this field of research is extensive (Roberts et al., 2016; Rogers et al., 2009; Sumnall and Cole, 2005) , which means there may be a substantial amount of unpublished research which failed to find neurocognitive deficits in ecstasy users. This problem is compounded when considering the possibility that currently available data have been consciously or unconsciously manipulated to support the researcher's biases. Conscious and unconscious manipulation of research data has been found in many areas of research (Bakker and Wicherts, 2011; Pashler and Wagenmakers, 2012; Simmons et al., 2011) and is not only a potential issue for ecstasy research.
Most studies examined in this review found more severe neurocognitive deficits in ''heavy'' ecstasy users. However, it would be interesting to know how many of those findings would be invalidated if standardized criteria were used for defining what a ''heavy'' ecstasy user is across studies. The implications of this issue are important. Research into the clinical use of MDMA for treating PTSD and other psychiatric disorders is hampered due to the legal status of MDMA, which is influenced by the academic literature that may exaggerate its harmful effects. There is a serious need for more effective treatments for PTSD. However, MDMA-assisted psychotherapy has shown great promise for treating the disorder (Bedi, 2018) . Ethically, we have a responsibility to investigate all effective treatments for people suffering from debilitating psychiatric disorders-and these investigations should not be hampered by flawed laws, which are influenced by flawed research.
Declaration of conflicting interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.
